Ganga Pharmaceuticals FY26 Net Profit Rises to ₹10.15 Lakh
Ganga Pharmaceuticals Limited announced its audited financial results for the fiscal year ended March 31, 2026, reporting a net profit of ₹10.15 lakh compared to ₹7.90 lakh in the previous year. Revenue from operations rose to ₹282.79 lakh, while total income reached ₹310.70 lakh. The company's paid-up equity share capital increased to ₹591.15 lakh following the conversion of warrants worth ₹112.88 lakh.
*this image is generated using AI for illustrative purposes only.
Ganga Pharmaceuticals Limited announced its audited financial results for the fiscal year ended March 31, 2026, on May 21, 2026. The Board of Directors approved the standalone financial results, which show an improvement in profitability and revenue for the full year. The statutory auditors, Banka & Banka, issued an audit report with an unmodified opinion on the annual financial results.
Financial Performance Overview
For the financial year ended March 31, 2026, the company reported a net profit of ₹10.15 lakh, compared to ₹7.90 lakh in the previous year. Revenue from operations rose to ₹282.79 lakh from ₹263.74 lakh in FY25. Total income for the period was ₹310.70 lakh, slightly higher than the ₹307.33 lakh recorded in the preceding year.
The half-year performance ending March 31, 2026, also reflected growth. Net profit for this half-year stood at ₹7.67 lakh, while revenue from operations reached ₹146.14 lakh. Total expenses for the full year increased marginally to ₹297.77 lakh from ₹297.86 lakh in the previous year.
Key Financial Metrics
The company’s earnings per share (EPS) for the full year improved to ₹0.17 on a basic and diluted basis, up from ₹0.16 and ₹0.12 respectively in the prior year. The paid-up equity share capital increased significantly to ₹591.15 lakh as of March 31, 2026, from ₹483.65 lakh in the previous year, following the conversion of warrants.
| Particulars | FY26 (₹ in Lakhs) | FY25 (₹ in Lakhs) |
|---|---|---|
| Revenue from Operations | 282.79 | 263.74 |
| Total Income | 310.70 | 307.33 |
| Total Expenses | 297.77 | 297.86 |
| Net Profit for the Period | 10.15 | 7.90 |
| Basic EPS (₹) | 0.17 | 0.16 |
Capital Structure and Cash Flows
During the current reporting period, Ganga Pharmaceuticals raised ₹112.88 lakh through the conversion of 10,75,000 warrants. Of this amount, ₹98.39 lakh was utilized for the objects stated in the issue document by March 31, 2026, with the unutilized balance of ₹14.48 lakh held in bank accounts.
The cash flow statement for the year ended March 31, 2026, revealed a net decrease in cash and cash equivalents of ₹24.42 lakh. Cash and cash equivalents at the end of the year stood at ₹5.82 lakh, comprising ₹1.38 lakh in cash on hand and ₹4.44 lakh in bank balances.
Historical Stock Returns for Ganga Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | 0.0% | 0.0% | +1.69% | -17.81% | +100.00% |
How does Ganga Pharmaceuticals plan to deploy the remaining ₹14.48 lakh in unutilized warrant proceeds, and what impact could this have on future revenue growth?
Given the significant decline in cash and cash equivalents to ₹5.82 lakh, how will the company manage its liquidity needs and fund potential expansion plans in FY27?
With the paid-up equity capital increasing by over 22% due to warrant conversions, could further equity dilution be expected, and how might this affect EPS trajectory going forward?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
